News

An online survey found that people living with HIV who had lower incomes are at a higher risk for household material hardships and poorer health outcomes.

This article highlights some key updates to the antimicrobial therapy recommendations in the updated community-acquired pneumonia guidelines.

Nurses stationed in public sexual health services and specialist HIV general physician practice study sites were integral in facilitating rapid PrEP uptake.

Since 2014 NYC Health + Hospitals has worked to maintain preparedness against diseases like Ebola.

This In the Literature piece features a case vignette on the de-escalation of antibiotics for culture-negative pneumonia.

A new review in The Lancet HIV discusses the next generation of HIV prevention, called PrEP 2.0.

A new study from ECDC investigators highlights mortality and risk factors associated with seasonal influenza.

After receiving FMT capsules containing drug resistant ESBL E coli, 2 patients developed severe illness with 1 patient death.

The FDA has authorized marketing of the Sentosa SQ HIV Genotyping Assay, which detects HIV-1 mutations in patients undergoing or about to initiate antiviral treatment.

Measles infection leaves patients vulnerable to a wide range of other pathogens by destroying antibodies for months or even years, according to a new study.

By repurposing the HIV treatment rilpivirine, investigators have opened up possibilities for treating Zika virus and other flavivirus infections which overlap with HIV.

Blood sample testing in African countries using rapid tests is a mixed message. Accuracy in HIV improved, but accuracy in hepatitis B and C testing did not.

Fluzone High-Dose Quadrivalent is given to people 65 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine.

Treating patients who have skin and soft tissue infections with a single dose of oritavancin may lower hospital admission rates compared to vancomycin, at a similar cost.

Assessing 195 countries’ capability to prepare, detect, and respond to outbreaks has found some major gaps.

A new commentary from NIAID experts suggests that we already possess many of the tools necessary to end the HIV epidemic, but that improving implementation is essential.

Study authors recommend further investigation of M72/AS01E for tuberculosis prevention and consider the trial results progress toward an efficacious vaccine.

RHB-105 (Talicia) is the only rifabutin-based therapy approved for the treatment of H pylori infection and is designed to address the high resistance of H pylori bacteria to current clarithromycin-based standard-of-care therapies.

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of October 27, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Epidemiologic and laboratory evidence indicates that ground beef is the likely source of the outbreak. The current hospitalization rate is 89%.

Until Hahn's position is confirmed, Brett Giroir, MD, of the Department of Health and Human Services, will serve as acting FDA Commissioner.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Researchers stumbled upon a resistant mutation in group A Streptococcus that confers reduced susceptibility to β-lactam antibiotics.

While the outbreak appears to be over, health officials are alerting the public and encouraging continued improvement of industry practices.

While most influenza vaccines target the binding protein hemagglutinin, a new study shows cross-strain results for treatment and prevention focused on the glycoprotein neuraminidase.

A rapid increase in antibiotic prescriptions before diagnosis with such conditions as COPD, heart failure and asthma, suggests these conditions may often be misdiagnosed as infections, according to a new study.

When a recent study unexpectedly found that pregnant women taking the isoniazid had a higher rate of poor pregnancy outcomes, a team from Johns Hopkins University set out to clarify the findings.